A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately modest bar for 2026, leaving investors to decide whether this is prudence or opportunity.
At first glance, GSK PLC's (LSE:GSK, NYSE:GSK) fourth-quarter results look like exactly what the market ordered. Revenue came in ahead of expectations, earnings beat by a wide margin, and the group quietly confirmed it has already delivered on the growth targets it set for the entire 2021–26 period.
But Shore Capital’s note cuts to the more interesting question. Not whether GSK beat the quarter, but why it chose to undersell the year ahead.
A strong finish, and a box ticked early
Q4 was comfortably better than consensus. Revenue of £8.6bn rose 8% at constant exchange rates, while core EPS jumped 14%. That combination pushed full-year 2025 performance to the top end of already-upgraded guidance.
More importantly, ShoreCap argues this effectively means GSK has hit its medium-term targets a year early. Sales growth and earnings progression are now where management said they would be by 2026. The longer-term ambition of more than £40bn of revenue by 2031 was reiterated without drama.
In isolation, this is exactly the sort of execution investors have been waiting to see since the Haleon demerger.
Specialty medicines are doing the heavy lifting
The quality of growth still matters, and here the picture is reassuring. Specialty Medicines grew 18% in the quarter, comfortably ahead of expectations, driven by injectable HIV products and oncology. This remains the engine of the group.
Vaccines also surprised on the upside. Shingrix and the RSV vaccine Arexvy both materially beat forecasts, offsetting continued weakness in General Medicines, which declined slightly year on year.
Cost control helped too. Lower-than-expected legal expenses, notably around Zantac, and a favourable tax outcome flattered earnings. At the same time, R&D spending stepped up as several oncology assets moved into pivotal trials, reinforcing the sense that management is choosing to invest rather than harvest.
Why 2026 guidance looks deliberately cautious
The most telling part of the update is not the quarter just gone, but the year ahead. GSK guided to 4–6% sales growth at constant exchange rates for 2026, with a sizeable foreign exchange headwind baked in.
ShoreCap’s view is blunt. This is a low bar. Consensus already sits near the top of the guidance range, and the broker expects numbers to drift down as FX assumptions are refreshed. Even then, it believes the guidance should be beatable given GSK’s exit rate from 2025.
There are real headwinds. US vaccine demand faces pressure from changes to CDC recommendations, while political noise around drug pricing is unlikely to disappear. General Medicines is still in decline. But the core growth engine remains intact, and the new CEO appears keen to reset expectations rather than chase them.
Capital returns remain supportive
There was no eye-catching new buyback announcement, but around £600m of repurchases are still expected in the first half. Dividends also came in ahead of forecasts, with 66p paid for 2025 and guidance pointing to 70p in 2026.
This matters because it reinforces the idea that GSK is no longer in balance-sheet repair mode. Cash generation is strong enough to fund R&D, maintain shareholder returns, and still absorb currency and pricing shocks.
Valuation is where the argument lies
Despite a strong run into the results, ShoreCap argues GSK still trades at a disproportionate discount to global peers. On its numbers, the shares sit on roughly 12–13 times forward earnings, versus 15–17 times elsewhere in big pharma.
The reason for that discount is well known. Investors remain unconvinced that GSK can grow cleanly through looming HIV patent expiries. This set of results does not remove that concern, but it does weaken the bear case.
Execution is improving. The pipeline is advancing. Guidance is conservative rather than promotional.
The paradox of GSK’s results is that the better the business performs, the less management seems willing to boast about it. For investors, that may be exactly the point.